Is Parkinson's disease a vesicular dopamine storage disorder?: Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum by Pifl, Christian et al.
Neurobiology of Disease
Is Parkinson’s Disease a Vesicular Dopamine Storage
Disorder? Evidence from a Study in Isolated Synaptic
Vesicles of Human and Nonhuman Primate Striatum
Christian Pifl,1 Alex Rajput,2Harald Reither,1 X Javier Blesa,3 Carmen Cavada,4 Jose´ A. Obeso,3 Ali H. Rajput,2
and Oleh Hornykiewicz1
1Center for Brain Research, Medical University of Vienna, A-1090 Vienna, Austria, 2Movement Disorders Program Saskatchewan, Royal University
Hospital, University of Saskatchewan, Saskatoon, Saskatchewan, SK S7N OW8, Canada, 3Movement Disorders Group, Neurosciences Division, CIMA, and
Department of Neurology and Neurosurgery, Clinica Universidad de Navarra, E31008 Pamplona, Spain, and 4Departamento de Anatomía, Histología y
Neurociencia, Facultad de Medicina, Universidad Auto´noma de Madrid, E28049 Madrid, Spain
The cause of degeneration of nigrostriatal dopamine (DA) neurons in idiopathic Parkinson’s disease (PD) is still unknown. Intraneuro-
nally, DA is largely confined to synaptic vesicles where it is protected frommetabolic breakdown. In the cytoplasm, however, free DA can
give rise to formation of cytotoxic free radicals. Normally, the concentration of cytoplasmic DA is kept at a minimum by continuous
pumping activity of the vesicular monoamine transporter (VMAT)2. Defects in handling of cytosolic DA by VMAT2 increase levels of
DA-generated oxy radicals ultimately resulting in degeneration of DAergic neurons. Here, we isolated for the first time, DA storage
vesicles from the striatum of six autopsied brains of PD patients and four controls andmeasured several indices of vesicular DA storage
mechanisms. We found that (1) vesicular uptake of DA and binding of the VMAT2-selective label [ 3H]dihydrotetrabenazine were
profoundly reduced in PD by 87–90% and 71–80%, respectively; (2) after correcting for DA nerve terminal loss, DA uptake per VMAT2
transport site was significantly reduced in PD caudate and putamen by 53 and 55%, respectively; (3) the VMAT2 transport defect
appeared specific for PD as it was not present in Macaca fascicularis (7 MPTP and 8 controls) with similar degree of MPTP-induced
nigrostriatal neurodegeneration; and (4) DA efflux studies andmeasurements of acidification in the vesicular preparations suggest that
the DA storage impairment was localized at the VMAT2 protein itself. We propose that this VMAT2 defect may be an early abnormality
promoting mechanisms leading to nigrostriatal DA neuron death in PD.
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Introduction
Idiopathic Parkinson’s disease is a chronic progressive neurode-
generative disease, biochemically characterized by loss of dopa-
mine (DA) in brain regions innervated by the nigrostriatal
pathway (Ehringer and Hornykiewicz, 1960; Hornykiewicz,
1998), linked to degeneration of the melanized, DA-containing
pars compacta perikarya of the substantia nigra (Hassler, 1938;
Greenfield and Bosanquet, 1953; Hornykiewicz, 1963; Gibb and
Lees, 1991). The cause of degeneration of the brain DA neurons is
still unknown. DA itself is easily (auto)oxidizable (Graham et al.,
1978), promoting formation of reactive oxygen species (Hastings
et al., 1996; Spencer et al., 1998), as well as normally metabolized
intracellularly by monoamine oxidase to DOPAC, with reactive
molecules as intermediates. In the last decades, involvement of
defective vesicular brain DA transport as triggering the “toxic-
DA-cascade” has attracted special attention (Edwards, 1993;
Miller et al., 1999; Uhl et al., 2000).
The vesicular monoamine transporter (VMAT)2 is a protein lo-
cated in the membrane of the synaptic vesicles where it serves two
purposes: neurotransmission and neuroprotection (Guillot and
Miller, 2009). In brain DA terminals, VMAT2 is responsible for the
packaging of cytoplasmic DA into synaptic vesicles, where the amine
is held ready for vesicular neurotransmitter release. High intrave-
sicular neurotransmitter concentrations are maintained by the
transporter’s continuous DA translocating activity driven by the H
electrochemical force generated by a vesicular H-ATPase
(Moriyama and Futai, 1990). Simultaneously, VMAT2 serves a neu-
roprotective purpose by keeping the concentration of the free cyto-
solic DA at a minimum (Mosharov et al., 2003). Failure of vesicular
DA sequestration results in reduced impulse-dependent DA release
(Imperato and Di Chiara, 1984; Millar et al., 1985; Fon et al., 1997;
Colliver et al., 2000) and accumulation of high free-cytosolic DA
(Mosharov et al., 2003, 2009; Vergo et al., 2007), potentially resulting
in production of DA-derived, cytotoxic reactive species (Caudle et
al., 2008).
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In laboratory experiments, pharmacological VMAT2 block-
ade with tetrabenazine irreversibly decreased the animals’ spon-
taneous activity and reduced the number of nigral DA neurons
(Satou et al., 2001), and administration of reserpine induced
signs of striatal oxidative stress (Fornstedt and Carlsson, 1989;
Spina and Cohen, 1989; Bilska et al., 2007) and, in nigral cell
cultures, DA-dependent oxidative cellular damage (Fuentes et al.,
2007). In brains from PD patients, reduction of striatal dihydro-
tetrabenazine (DTBZ)-binding as a measure of VMAT2 levels,
was less than the loss of striatal DA (Wilson et al., 1996), indicat-
ing a defective DA storage with fewer than normal DA molecules
in each parkinsonian vesicle; this being concurrent with an earlier
suggestion that “in PD a ‘reserpine-like principle’ might be active
in the brain” (Hornykiewicz, 1964). Recently, a DA storage defect
has been deduced from a study of catechol patterns of PD puta-
men (Goldstein et al., 2013).
Here, we for the first time provide direct evidence for, and
describe the nature of a primary defect in DA transport function
of the VMAT2 directly in synaptic vesicles isolated from the stria-
tum of patients dying with PD. We suggest that this defect may be
an early critical abnormality promoting degenerative death path-
ways underlying the progressive death of nigrostriatal DA neu-
rons in this disorder.
Materials andMethods
Human brain tissue. Autopsied brains were obtained from six neuro-
pathologically confirmed PD cases (66 – 84 years; 3 female, 3 male), and
four control subjects (68 – 88 years; 1 female, 3 male) without evidence in
their records of any neurological or psychiatric disorder. Clinical infor-
mation, drug history and major neuropathological findings of the pa-
tients with PD are shown in Table 1. The mean age (SEM) of the
control and PD patient groups (79.0 4.4 years, range: 68 – 88 years and
76.3 3.2 years, range: 66 – 84 years, respectively) did not differ signifi-
cantly nor did the mean postmortem time ( death to autopsy interval;
controls; 12.8 1.9 h, range: 7–15.5 h; patients; 9.4 2.2 h, range: 5–20
h). At autopsy, brains were divided by a midsagittal section into two hemi-
spheres, with one half-brain immediately frozen for neurochemistry, and the
other half-brain preserved for neuropathological examination. For our
study, the frozen half-brains were thawed to approximately10°C and cut
by hand in the frontal plane in 3- to 5-mm-thick slices, starting at the
anterior border of the caudate head. For the preparation of synaptic vesicles
tissue samples from slices of midcaudate (head) and midputamen slices were
taken and stored at80°C until analyses.
MPTP monkey tissue. Putamen samples from male macaque monkeys
(Macaca fascicularis) were used, derived from our recent study on
MPTP-induced neurodegeneration (Blesa et al., 2012). MPTP (Sigma-
Aldrich) was systemically administered using a dose regimen of 0.5
mg/kg (i.v.) every 2 weeks until a stable parkinsonian state with persis-
tent, clearly recognizable parkinsonian features was obtained. Animals
were housed in an animal room under standard conditions and treated in
accordance with the European and Spanish guidelines (86/609/EEC and
2003/65/EC European Council Directives; and the Spanish Govern-
ment). The Bioethics Committees of the Universidad de Navarra and the
Universidad Auto´noma de Madrid approved the experiments. None of
these monkeys received treatment with any antiparkinsonian drug or any
other therapeutic intervention at any time during the study. The mon-
keys were killed at least 4 weeks after the last MPTP administration using
deep anesthesia with pentobarbital, the brains removed and divided by a
midsagittal section into two hemispheres, one of which was immediately
frozen at80°C and kept frozen until vesicle preparation.
Preparation of synaptic vesicles. Samples of approximately 550 –700 mg
of human striatal tissue (50 – 80 mg of monkey putamen) were homog-
enized in ice-cold 0.3 M sucrose containing 25 mM Tris, pH 7.4, and 10M
pargyline, using seven up– down strokes in a glass Teflon Potter-type
homogenizer and the whole further procedure was performed at 4°C. For
DA and homovanillic acid (HVA) determination (see below), a 20 l
aliquot was diluted in 380 l of 0.1 M perchloric acid containing 0.4 mM
sodium bisulfite and 8 ng 3,4-dihydroxybenzylamine as internal stan-
dard. The sucrose-homogenate was centrifuged at 1000  g for 15 min
and the supernatant recentrifuged at 20,000 g for 30 min. The resulting
pellet (“P2”) was subjected to osmotic shock by the addition of deionized
H2O (caudate tissue was homogenized in 4 ml using up– down strokes in
the Potter, putamen tissue was resuspended in 1 ml H2O, frozen for15
min, and after thawing, also homogenized in a total of 4 ml H2O). The
aqueous samples were centrifuged at 22,000  g for 15 min and osmo-
larity of the supernatant was readjusted by addition of 1.3 M potassium
phosphate buffer, pH 7.4, in 1/10 the volume. The supernatant of the
20,000 g centrifugation (see above) was centrifuged at 100,000 g for
30 min and the resulting pellet was resuspended in the 3.7 ml of the
22,000 g supernatant readjusted to 0.13 M potassium phosphate, thus
combining vesicles in the supernatant of the P2 pellet and in the hypo-
osmotically shocked P2 pellet. On each preparation from human tissue,
vesicular uptake and efflux were done in parallel and one aliquot was kept
for later [ 3H]DTBZ binding. For efflux 1.66 ml of each preparation
(obtained from 250 –320 mg human tissue) was incubated in a total
volume of 6 ml assay buffer KP (0.13 M potassium phosphate, pH 7.4) in
the presence of 2 mM MgATP and 0.1 M [ 3H]DA in a 30°C water bath
for 4 min and then centrifuged at 4°C at 100,000 g for 45 min. The rest
of the preparation was split in half and similarly incubated and centri-
fuged in the absence of [ 3H]DA, obtaining one pellet for uptake and the
other for proton gradient measurement.
Vesicular uptake. The pellet for uptake was resuspended in KP to ob-
tain 4.75 ml vesicle suspension. Uptake was performed in a total volume
of 1.5 ml KP containing 2 mM MgATP and various concentrations of
[ 3H]DA (New England Nuclear GmbH). Unspecific uptake was deter-
mined in the presence of 1 M reserpine. Transport was initiated by
placing the tubes in a 30°C water bath and adding 0.5 ml vesicle suspen-
sion (obtained from20 –25 mg human and 6 – 8 mg of monkey tissue)
for the desired intervals of time. Uptake was terminated by the addition of 2.5
ml ice-cold KP, immediate filtration under vacuum onto Whatman GF/B
filter paper presoaked in 1% polyethylenimine, using a Brandel harvester.
The filters were washed twice with additional 3 ml of cold KP.
Vesicular efflux. The pellet of [ 3H]DA loaded vesicles (see above) was
resuspended in 7.75 ml efflux buffer (0.13 M potassium phosphate, 20 mM
Table 1. General characteristics of PD patients
Case
no.
Age at
death/gender
Clinical diagnosis
(duration of
disease, years) PD medication
Primary cause
of death Brain pathology
Postmortem
(death to autopsy)
interval, h
1 82/F iPD (8) Levodopa/carbidopa Respiratory failure SN cell loss LB 8.5
2 82/F iPD (18) Levodopa/benserazide, amantadine (none for 1 month
before death)
Respiratory failure marked SN/LC cell loss LB 8
3 66/F iPD (13) Levodopa/carbidopa (last dose 2 weeks before death) Colon cancer mild to moderate SN/LC cell loss LB 6
4 76/M iPD (10) Levodopa/benserazide (last dose just before death) Cardiovascular failure moderate to marked SN/LC cell loss LB 9
5 84/M iPD (16) Levodopa/carbidopa (last dose 1 h before death) Cardiac failure marked SN/LC cell loss LB 5
6 68/M iPD (23) Levodopa/carbidopa, amantadine, bromocriptine Pulmonary embolism,
cardiac arrest
marked SN/LC cell loss LB 20
iPD, Idiopathic PD; LB, Lewy body; SN, substantia nigra; LC, locus coeruleus.
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MgATP, 10 M ascorbate, 10 M pargyline, pH 7.4) at 4°C in the cold
room and kept on ice. Efflux was done parallel to vesicular uptake (see
above) for each preparation. Aliquots of 500 l were incubated at 30°C
for the times indicated; three samples in the presence of 0.1 mg/L nige-
ricin. Efflux was terminated by filtration as in uptake experiments.
[3H]DTBZ binding. Vesicle suspension (1.5 ml) put aside from vesic-
ular uptake experiments for each preparation, were centrifuged at
100,000 g for 30 min at 4°C and the pellet was resuspended in 125l of
binding buffer SP (25 mM sodium phosphate, pH 7.7) and frozen at
80°C until the binding experiment. This was performed in SP at a total
volume of 75 l by incubating 25 l buffer, 25 l 4 nM ()-a-
dihydrotetrabenazine [2- 3H] (American Radiolabeled Chemicals), and
25 l thawed preparation for 90 min at 30°C; unspecific binding was
determined by the presence of 1 M tetrabenazine. Binding was termi-
nated by the addition of 2.5 ml ice-cold SP, immediate filtration under
vacuum onto Whatman GF/B filter paper, using a Brandel harvester. The
filters were washed twice with additional 3 ml of cold SP.
Protein gradient measurement. Synaptic vesicles were prepared from
200 –250 mg putamen tissue, finally resuspended in 550l KP and half
of it frozen for DA measurement after mixing with one-tenth of 1 M
perchloric acid containing 4 mM sodium bisulfite and 0.3 ng 3,4-
dihydroxybenzylamine as internal standard. Acidification of vesicles was
measured in duplicates by ATP-dependent quenching of acridine orange
fluorescence at 493 nm (excitation) and 530 nm (emission) in a Hitachi
F-4500 fluorescence spectrophotometer (Nelson et al., 1988). Vesicular
preparations (120 l; or KP for subtraction of a blank trace) were mixed
with 2.880 l reaction medium RM (0.241 M sucrose, 5 mM Tricine-
NaOH, pH 8.0, 80 mM KCl) and incubated in a 3 ml cuvette containing a
small magnetic stirrer and tempered at 30°C for 2 min. Then 6 l 1 mM
acridine orange was added, recording of emission was started 2 min later.
Fifteen microliters of 0.1 M MgATP was added 1 min and 3 l carbonyl
cyanide p-trifluoromethoxyphenylhydrazone (FCCP; 1 mM in ethanol) 5
min after the start of recording.
Determination of DA and HVA. DA, serotonin (5-HT), DOPAC, and
HVA were determined by means of high-performance liquid chromatog-
raphy with electrochemical detection as described previously (Blesa et al.,
2012).
Calculations and statistics. The DAergic contribution proper to stri-
atal vesicular uptake per VMAT2 transport site (upt/site) in PD was
calculated by DAPD/(DAPD5-HTPD)  (upt/site)DA,PD  5-HTPD/
(DAPD5-HTPD) (upt/site)5-HT,PD (upt/site)PD, with DAPD (puta-
men: Table 2; caudate: 1.00 0.49g/g) and 5-HTPD (putamen: 0.091
0.025; caudate: 0.062 0.015 g/g) being DA and 5-HT tissue levels in
PD and the assumption of unchanged (Control) VMAT2 function (in
contrast to the number of transport sites) in vesicles from 5-HTergic
nerve terminals, (upt/site)5-HT,PD  (upt/site)Control. Data are reported
as mean  SE. Statistical analysis was done using two-sided unpaired
Student’s t test.
Results
Characterization of vesicular DA uptake in human
postmortem tissue
Due to the limited amount of human striatal postmortem tissue
available, we first optimized the protocol in preliminary experi-
ments. In agreement with reports on vesicular transport in super-
natants of a P2-pellets of a crude synaptosomal preparation
(Philippu and Beyer, 1973; Seidler et al., 1977) and reports on
vesicular transport in H2O-lysates of P2-pellets (Whittaker et al.,
1964; Erickson et al., 1990) we also found reserpine-sensitive and
ATP-dependent DA uptake in both preparations (data not
shown) and therefore combined both of them for maximal yield
in all further experiments of this study.
Experiments on time-dependence of uptake showed linearity
for up to 4 min of incubation (Fig. 1A) and a time interval of 4
min was used in further experiments. There was a linear tissue-
dependence up to 150g protein per tube (Fig. 1B); nevertheless,
to rule out any effects of concentration, we used for vesicular
preparations about the same amounts of tissue of each of the PD
and control cases and performed the uptake, efflux, binding, and
fluorometric assays with similar amounts of protein per tube (see
below). Scatchard analysis of DA-dependence of uptake experi-
ments (Fig. 1C) gave KM values in the range of 0.3M, and 0.1M
of DA was used in further uptake experiments. DA uptake by the
vesicular preparation was reserpine-sensitive and ATP-
dependent and much higher in the putamen than in thalamic
tissue with low monoaminergic innervation (Fig. 1D).
Reserpine-sensitivity and ATP-dependence as well as the use
of a sodium- and chloride-free potassium phosphate buffer
rules out the possibility of any distorting contribution of the
plasmalemmal sodium- and chloride-dependent DA transporter.
DA-uptake into synaptic vesicles from caudate of PD and controls
We first determined specific vesicular DA uptake in the caudate.
Compared with control, in caudate of PD patients vesicular DA
uptake was profoundly reduced by 87% (Fig. 2A). Because this
reduction may reflect both a reduced number of nerve endings
and an impaired VMAT2 activity, we determined the overall
number of VMAT2 sites in each vesicular preparation by binding
of the VMAT2-selective label [ 3H]DTBZ which was also highly
reduced in PD by 71% (Fig. 2B). The calculated ratio of DA
uptake to [ 3H]DTBZ binding, reflecting number of transported
DA molecules per unit time per VMAT2 transport site, was re-
duced in PD by 53% (Fig. 2C; p  0.022 by Student’s t test).
Corrected for the VMAT2 in 5-HT terminals, the calculated (see
Materials and Methods) reduction was by 56% of controls.
DA-efflux from vesicles in the caudate of PD and controls
We loaded an aliquot of each of the vesicular preparations with
[ 3H]DA, removed the extracellular tracer by centrifugation at
4°C and measured efflux of the stored DA by incubating the
vesicles at 30°C for various time intervals and determined the
remaining intravesicular tritium. There was a time-dependent
reduction of vesicular tritium, in absolute amounts at a lower
level in PD (Fig. 2D); however, efflux was clearly not faster but
slightly attenuated compared with controls if data were normal-
ized to the initial levels of loaded tritium (p 0.039 at 10 min by
Student’s t test; Fig. 2E). Quantitatively, efflux rates were consid-
erably lower than uptake rates (controls: 0.3 pmol/min vs 3.3
pmol/min; PD: 0.1 pmol/min vs 0.4 pmol/min); therefore the
20% reduction of efflux in PD cannot be construed as signifi-
cantly compensating the effect of reduced uptake on cytosolic DA
concentrations. To examine the background of not releasable DA
Table 2. DA, DOPAC, HVA tissue levels, and DA turnover in patients with PD and
MPTPmonkeys
Control
Parkinson’s
disease/MPTP
Human putamen
DA (g/g) 3.98 1.03 0.14 0.07***
DOPAC (g/g) 0.285 0.110 0.040 0.012*
DOPAC/DA (molar ratio) 0.071 0.020 0.393 0.070**
HVA (g/g) 5.55 0.71 2.45 0.94*
HVA/DA (molar ratio) 1.52 0.46 22.09 6.41*
Monkey putamen
DA (g/g) 13.26 0.51 0.46 0.08***
DOPAC (g/g) 0.951 0.060 0.178 0.007***
DOPAC/DA (molar ratio) 0.067 0.007 0.460 0.103***
HVA (g/g) 20.19 0.46 4.13 0.35***
HVA/DA (molar ratio) 1.29 0.05 9.08 1.50***
*p 0.05, **p 0.01, ***p 0.002 of PD orMPTP versus Control by Student’s t test. Values are given asmean
SEM.
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in the preparation and in search for a difference between controls
and PD, we measured efflux for 2 min in the presence of the
ionophore nigericin at a threshold concentration based on pre-
liminary experiments on control tissue. In both, control and PD
preparation nigericin reduced the intravesicular tritium levels to
approximately the levels obtained after 10 –30 min of efflux and
the values in the presence of nigericin were significantly higher in
PD than in control samples if normalized to initial levels of
loaded tritium (p 0.030 by Student’s t test;Fig. 2D,E).
DA-uptake and efflux in the putamen of PD and controls
In a second, independent experiment we performed the same
experiments in tissue from the putamen. There was again a
marked decrease of absolute DA uptake (Fig. 3A) and [ 3H]DTBZ
binding (Fig. 3B) in PD putamen by 90 or 82%, respectively, with
the uptake rate per transport site showing a significant reduction
by 55% (Fig. 3C; p 0.032 by Student’s t test); corrected for the
VMAT2 in 5-HT terminals (for calculations, see Materials and
Methods) the reduction per DA transport site amounted to 90%.
Although in controls there were lower uptake rates per transport
site in putamen than in caudate (0.97 0.17 vs 2.81 0.54, p
0.017 by Student’s t test), a slightly different protocol of prepara-
tion (freezing of the P2-pellet of putamen before lysis for obtain-
ing a higher yield of vesicles) makes a direct comparison of the
data questionable. Findings in efflux experiments in controls and
PD were similar to caudate and did not reveal impaired retention
of DA in vesicles of PD putamen (Fig. 3D,E).
DA-uptake in the putamen of MPTP monkeys and controls
Obviously, the main difference between control and PD striatal
tissue is the severe reduction of DAergic nerve terminals in PD as
reflected by the 90% reduction of absolute values of vesicular
DA uptake. Theoretically, the reduced VMAT2 uptake rate per
transport site in PD might be due to the specific situation of
“diluted” vesicular transporter sites in the denervated striatal tis-
sue. Therefore, we compared our results in PD with results ob-
tained in vesicular preparations from tissue of MPTP-treated
monkeys with a comparable degree of DAergic denervation (pu-
tamen DA in percentage of control: 3.56 1.85, PD; 3.45 0.63,
MPTP monkeys). MPTP administration resulted in a 92% reduc-
tion of vesicular DA uptake in preparations of monkey putamen
(Fig. 4A); however if the reduction of [ 3H]DTBZ binding (Fig.
4B) sites was taken into account, the uptake rate per monoamine
transport site was unchanged compared with controls (Fig. 4C).
DA and metabolites in the putamen of PD, MPTP-monkeys and
in vesicles of PD and controls
Increased HVA/DA and DOPAC/DA ratios in PD striatum can
be due to either a compensatory increase of DA turnover or an
impaired DA sequestration in vesicles. We therefore measured
DA and HVA in the same putamen samples from which vesicles
were prepared by precipitating an aliquot from the initial sucrose
homogenates with perchloric acid (Table 2). DA levels were re-
duced by 96% in humans with PD and by 97% in monkeys with
MPTP-parkinsonism, with HVA and DOPAC reductions of 56
Figure 1. DA uptake by synaptic vesicles prepared from human control striatal tissue. A, Time-dependence of DA uptake. Synaptic vesicle preparations from striatum were incubated in the
absence or presence of 1M reserpine with 0.3M [ 3H]DA at 30°C for the times indicated. Specific uptake (filled symbols, solid line) was calculated by subtraction of unspecific from total uptake.
Data shown aremean values of triplicates.B, Protein-dependence of DA uptake. Synaptic vesicle preparations from caudate/putamen at the protein amounts indicatedwere incubatedwith 0.1M
[ 3H]DA at 30°C for 4 min in the absence or presence of 1M reserpine. Data shown are mean values of triplicates. C, Concentration-dependence of DA uptake. Synaptic vesicle preparations from
striatumwere incubated with [ 3H]DA at the concentration indicated at 30°C for 4 min in the absence or presence of 1M reserpine. Inset, Scatchard transformation of specific uptake. Data shown
are mean values SE of three independent experiments, each done in triplicates. D, ATP-dependence and striatal specifity of DA uptake. Synaptic vesicle preparations (33–35g protein) of
putamen or thalamus were incubated with 0.3M [ 3H]DA at 30°C for 4 min in the absence or presence of 1M reserpine and 2 mM MgATP. Data shown are mean values of triplicate.
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and 86% in PD, and 80 and 81% in MPTP monkeys, respectively,
resulting in significantly increased HVA/DA and DOPAC/DA
ratios in both PD and MPTP with the ratios calculated from the
final metabolite HVA being more than twofold higher in PD than
in MPTP primate (Table 2). To estimate a potential interference by
the endogenous DA retained in our vesicular preparations with the
in vitroDA uptake, we determined the residual DA levels in vesicular
fractions prepared from putamen. Vesicular DA levels were 96.1
7.8 fmol/mgprot (n  4) in controls and 8.7  4.8 (n  5) in PD.
Relative to the number of [3H]DTBZ binding sites, residual DA
levels per VMAT2 binding site (pmolDA/pmolDTBZ) were clearly not
increased in PD, with 0.047 0.010 (n 4) in controls and 0.021
0.009 in PD (n 5; difference not significant).
Proton uptake into vesicles from putamen of PD and controls
Because monoamine uptake into vesicles is driven by the proton
gradient at the vesicular membrane, we determined fluorescence
of acridine orange taken up into putamen vesicle preparations
which reflects ATP-dependent proton uptake into vesicles. There
was no difference between controls and PD, neither for the ATP-
induced acidification (decrease of fluorescence after the ATP-
addition at 60 ms), nor for the breakdown of acidity induced by
carbonyl cyanide FCCP (increase of fluorescence after the addi-
tion of the ionophore at 300 ms; Fig. 5).
Discussion
To our knowledge, experiments on the functional state of the
VMAT2 in synaptic vesicles isolated from autopsied human brain
tissue, have never been reported previously. Here, we present
direct evidence for an impaired vesicular uptake of DA in the
striatum of patients with PD. Our results indicate a compromised
capability to sequester DA within the striatal DAergic nerve ter-
minals in this disorder.
Figure 2. Synaptic vesicles prepared from caudate of patients with PD and controls. A, Spe-
cific DA uptake. Synaptic vesicle preparations (16 4 and 19 3g protein for controls and
PD, respectively) were incubated in the absence or presence of 1 M reserpine with 0.1 M
[ 3H]DAat 30°C for 4min; **p0.002 specific uptake in PD versus control by Student’s t test.B,
DTBZ-binding. Synaptic vesicle preparations (3.7 1.6 and 4.2 0.7g protein for controls
and PD, respectively) were incubated in the absence or presence of 1M tetrabenazine with 4
nM [ 3H]DTBZ at 30°C for 90min; **p 0.004 specific binding in PD versus control by Student’s
t test. C, Uptake per DTBZ-binding site. For each synaptic vesicle preparation specific DA uptake
was divided by specific DTBZ-binding; *p 0.03 uptake rate per transport site in PD versus
control by Student’s t test. D, DA efflux. Synaptic vesicle preparations were loaded with DA by
incubationwith 0.1M [ 3H]DA at 30°C for 4min, centrifuged and the pellet resuspended at 4°C
and finally incubated at 30°C for 2 (in the presence and absence of 0.1 mg/L nigericin), 10, and
30 min. DA retained was determined by filtration. E, DA efflux presented in percentage of
loaded DA. *p 0.05 efflux in PD versus control by Student’s t test. Data shown are mean
values SE of four controls and six PD cases, each done in triplicate.
Figure 3. Synaptic vesicles prepared from putamen of patients with PD and controls. A,
Specific DA uptake. Synaptic vesicle preparations (28  5 and 31  6 g protein for
controls and PD, respectively) were incubated in the absence or presence of 1 M reser-
pine with 0.1 M [ 3H]DA at 30°C for 4 min; **p 0.00001 specific uptake in PD versus
control by Student’s t test. B, DTBZ-binding. Synaptic vesicle preparations (6.5 0.71
and 8.0 1.3g protein for controls and PD, respectively) were incubated in the absence
or presence of 1M tetrabenazine with 4 nM [ 3H]DTBZ at 30°C for 90 min; **p 0.0005
specific binding in PD versus control by Student’s t test. C, Uptake per DTBZ-binding site.
For each synaptic vesicle preparation specific DA uptake was divided by specific DTBZ-
binding; **p 0.05 uptake rate per transport site in PD versus control by Student’s t test.
D, DA efflux. Synaptic vesicle preparations were loaded with DA by incubation with 0.1M
[ 3H]DA at 30°C for 4 min, centrifuged and the pellet resuspended at 4°C and finally
incubated at 30°C for 2 (in the presence and absence of 0.1 mg/L nigericin), 10, and 30
min. DA retained was determined by filtration. E, DA efflux presented in percentage of
loaded DA. *p 0.05 of release in PD versus control by Student’s t test. Data shown are
mean values SE of four controls and six PD cases, each done in triplicate.
8214 • J. Neurosci., June 11, 2014 • 34(24):8210–8218 Pifl et al. • Vesicular Dopamine Transport in PD
Compared with controls, in PD the uptake rate of DA per
vesicular monoamine transport site was reduced both in caudate
and putamen by 53 and 55%, respectively; calculated per vesicu-
lar DA transport site proper the loss was 56% in caudate and 90%
in putamen. The magnitude of striatal VMAT2 function loss
appears functionally highly relevant. VMAT2 transgenic mouse
lines expressing5–10% of normal VMAT2 have been recently
shown to develop, in addition to severe striatal DA loss, a DA
dysfunction with indices of oxidative stress, (retrograde) nigro-
striatal DA neurodegeneration and behavioral features of PD sen-
sitive to L-DOPA (Caudle et al., 2007). Thus, it appears that
VMAT2 deficiency alone can initiate brain changes similar to
what characterize PD. Also, recently a mutation in the VMAT2
gene has been found in children of an extended consanguineous
family with parkinsonism as the clinically leading phenotype sen-
sitive to DA agonist treatment (Rilstone et al., 2013). In any case,
the DA transport defect in our patients does appear to be a feature
of PD, being neither an aspect of the great variability of normal
VMAT2 protein expression nor due to some, as yet unknown
alteration of vesicular transport activity in PD nerve terminals
“thinned out” by the neurodegenerative process. Thus, compa-
rable degree of degeneration of nigrostriatal (putamen) DAergic
terminals produced by MPTP in our cynomolgus monkeys did
not reduce the uptake of DA per vesicular transport site.
Human versus monkey control postmortem striatal tissue
Absolute amounts of DA taken up in vesicular preparations of
putamen were more than 10-fold higher in control monkeys than
human controls. This could be due to species differences or dif-
ferent time intervals between death and freezing of the brain,
5–10 min for monkeys versus 5–20 h for humans. There was no
difference of postmortem interval between parkinsonian and
control brains, neither in humans nor in monkeys ruling out any
bias for comparisons PD/MPTP subjects and the respective con-
trols. Absolute striatal DA and HVA tissue levels were also higher
in monkeys than in humans; the quite similar HVA/DA ratios of
human and monkey controls, however, point to a true species
difference and therefore comparability of
these DAergic parameters between hu-
mans and monkeys.
Retention of DA in monoamine vesicles
The reduced uptake per monoamine
transport site in PD could result from re-
duced vesicular retention of DA within
the 4 min incubation time of the uptake
assay. However, we found no indication
for a leakage of the vesicular membrane,
with the time-dependent loss of DA from
preloaded and washed vesicles being the
same between PD and controls; also the
ionophore nigericin did not reduce DA
retention to a greater extent in PD than in
control samples. In fact, efflux of DA was
slightly, but significantly attenuated from
preloaded PD vesicles as compared with
controls; however, the much lower efflux
than uptake rates annul any compensa-
tion by the reduced efflux of a potential
increase of cytosolic DA consequent to re-
duced uptake rates. Furthermore, residual
endogenous DA in vesicular preparations
from PD putamen were actually (not sig-
nificantly) lower than from controls
which rules out retained DA as a mechanism of reducing in vitro
uptake specifically in PD.
Proton gradient in striatal vesicle preparations
Impaired transport of DA into synaptic vesicles can result from a
change of the transporter protein VMAT2 or a reduced proton
gradient provided by the H-ATPase. Acidification as measured
by ATP-dependent quenching of acridine fluorescence was not
different between vesicular preparations from PD and control
putamen, nor was the abolishment by the protonophore FCCP.
Therefore, we have no indication for a dissipating effect on the
pH gradient in PD synaptic vesicles.
Maximal velocity versus affinity
The reduced DA uptake per monoamine transport site in PD
could be due either to reduced maximal uptake velocity of
VMAT2 or reduced affinity for the substrate DA. This could be
resolved by doing complete uptake-concentration curves in each
PD and control case; however, this was not possible due to the
limited amounts of striatal tissue available. A distinction between
reduction of maximal velocity versus reduced affinity to DA is
interesting from a mechanistic point of view. On the functional
level, however, both mechanisms would reduce DA clearance
from the cytosol, considering that cytosolic DA concentrations
are far below the KM of vesicular uptake (Mosharov et al., 2009).
Relevance to the ethiopathogenesis of PD
Inhibition or downregulation of the DA sequestering function of
VMAT2 was recently directly shown to increase cytosolic cate-
chol/DA concentrations (Mosharov et al., 2003, 2009; Vergo et
al., 2007), and in vivo accumulation of cytosolic DA alone proved
sufficient to trigger oxidative stress and neurodegeneration
(Chen et al., 2008). Granting that our observations reflect the
situation in vivo, they can be taken as indicating increased cyto-
solic DA levels in PD striatum in vivo, an abnormality possibly
already established in the preclinical phase of the disease (see
below). This in turn could lower the threshold for several path-
Figure 4. Synaptic vesicles prepared from putamen of MPTP monkeys and controls. A, Specific DA uptake. Synaptic vesicle
preparations (25 3 and 26 2g protein for controls andMPTP, respectively) were incubated in the absence or presence of 1
M reserpine with 0.1M [ 3H]DA at 30°C for 4 min; **p 0.00001 specific uptake in MPTP versus control by Student’s t test. B,
DTBZ-binding. Synaptic vesicle preparations (16 2 and 16 1g protein for controls andMPTP, respectively) were incubated
in the absence or presence of 1M tetrabenazinewith 4 nM [ 3H]DTBZ at 30°C for 90min; **p 0.00001 specific binding inMPTP
versus control by Student’s t test. C, Uptake per DTBZ-binding site. For each synaptic vesicle preparation, specific DA uptake was
divided by specific DTBZ-binding. Data shown are mean values SE of eight control and seven MPTP monkeys, each done in
triplicate.
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ways of striatal DAergic neurodegenera-
tion in patients. Our inability to obtain
autopsied brains of patients in the pres-
ymptomatic phase of PD is an obvious
limitation imposed on our study.
In addition to VMAT2 dysfunction,
other proposed mechanisms of DA neu-
ronal death (complex I inhibition; mito-
chondrial failure, misfolded proteins)
increase intracellular oxidant stress (Jen-
ner, 1998; Tabner et al., 2002; Dauer and
Przedborski, 2003; Hauser and Hastings,
2013) thereby potentially damaging the
VMAT2 protein (Eyerman and Yamamoto,
2007; Watabe and Nakaki, 2008) or the
V-type H-ATPase proton pump (Ter-
land et al., 2006). However, the vesicular
DA uptake per transport site was quite un-
affected in our MPTP parkinsonian mon-
keys despite the fact that striatal oxidative
stress is well established in MPTP treated
animals, with superoxide and nitric oxide
participating in the neurotoxic process
(Przedborski et al., 2000). Oxidative VMAT2
damage would also be expected consequent to
administration of L-DOPA which has been
shown to increase free cytosolic DA in ventral
midbrain DA neurons of mice in ex vivo ex-
periments (Mosharov et al., 2009). There is,
however, no clinical evidence for L-DOPA be-
ing detrimental to the progression of PD
symptoms (Parkinson Study Group, 2004),
and also in our L-DOPA treated patients no
correlationwasdetectablebetweentimeof last
L-DOPA dose before death and VMAT2
transport dysfunction. Together caution in
drawing far-reaching conclusions about clini-
cal and/or causative relevance of the available
experimental data appears in order.
What then could have been the pri-
mary event reducing vesicular striatal DA
uptake per VMAT2 transport site in our
patients? Of the environmental neuro-
toxicants of industrial and natural origin
affecting brain VMAT2 or DA neuron in-
tegrity (Betarbet et al., 2000; Fonnum and
Mariussen, 2009; Inamdar et al., 2013),
some organochlorine compounds have
been detected in PD brains (Corrigan et
al., 2000) suggesting possible environ-
mental impact on severity or progression
of the disease. Nonetheless, PD is not a disease of the modern
industrial era (Parkinson, 1817); therefore, genetic factors pre-
disposing to PD are most conspicuous. Although functional mu-
tations in the coding region of SLC18A2 (VMAT2) have not been
detected in patients with idiopathic PD (Glatt et al., 2006), two
recent genome-wide association studies found increased suscep-
tibility to idiopathic PD in common variants of the -synuclein
gene (Satake et al., 2009; Simon-Sanchez et al., 2009). Indeed, a
modulation of VMAT2 protein expression by mutant or wild-
type human -synuclein was reported in several studies (Lo-
tharius and Brundin, 2002; Lotharius et al., 2002; Guo et al.,
2008) and lowering synuclein levels in human DAergic neuro-
blastoma cells increased total VMAT2 particle density and num-
ber of VMAT2 particles per vesicle (Fountaine et al., 2008).
However, the above alterations would not necessarily result in
our finding of reduced DA uptake per monoamine transport site.
Significantly, elevated -synuclein levels were recently found in
individual surviving neurons of idiopathic PD substantia nigra
(Gru¨ndemann et al., 2008), in principle permitting increased ve-
sicular -synuclein-VMAT2 interactions which had been de-
tected in yeast-two hybrid or GST pull-down experiments (Dean
et al., 2007; Guo et al., 2008). Furthermore, -synuclein-VMAT2
complexes have been detected in normal human striatum (Guo et
al., 2008) and -synuclein-VMAT2 aggregates in (swollen) dys-
Figure 5. Protein gradient measurement on synaptic vesicles prepared from putamen of patients with PD and controls. Syn-
aptic vesicle preparations (47 4 and 48 7g protein for controls and PD, respectively) were incubated with 2M acridine
orange and acidificationwasmeasured by quenching of fluorescence at 493 nm (excitation) and 530 nm (emission) after addition
of 0.5mMMgATP at 60 s and proton gradient abolition by addition of 1M carbonyl cyanide FCCP at 300 s. Shown aremean values
of fluorescent traces shifted to 0 fluorescence at the time interval 0–58 s SE (gray area) of four controls (A) and six PDpatients (B).
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trophic striatal DA axons and terminals in the AAV--synuclein
rat model of nigrostriatal neurodegeneration (Lundblad et al.,
2012). Collectively, these observations allow for the occurrence of
-synuclein-VMAT2 interactions with increased formation of
striatal -synuclein-VMAT2 complexes in DA neurons, which
might account for our specific finding of reduced vesicular DA
uptake per striatal VMAT2 transport site. Previous studies have
shown that VMAT2 function decisively regulates synaptic DA
release by affecting its quantal size (Fon et al., 1997; Pothos et al.,
2000), and both moderate reductions of VMAT2 in heterozygous
knock-out mice (Fon et al., 1997; Wang et al., 1997), and overex-
pression of -synuclein (Gaugler et al., 2012; Lundblad et al.,
2012; Janezic, 2013) impaired synaptic DA release well before
neuronal degeneration. Considering that VMAT2 and -syn-
uclein are essentially expressed at the presynaptic level, our find-
ings suggest that in PD the initial events start, likely in the
preclinical phase, at synaptic terminals rather than in soma. This
might have important therapeutic implications aiming to halt
neurodegeneration of the nigro-striatal system.
In conclusion, we report for the first time a defect in the ve-
sicular DA transport machinery in synaptic vesicles isolated from
the striatum of patients with PD. The impairment of the vesicular
DA uptake appears to be localized at the VMAT2 protein itself,
either in as yet unknown posttranslational modifications, or
more likely, VMAT2-interacting molecules. We propose that this
VMAT2 defect may be an early abnormality promoting several
neurodegenerative pathways ultimately leading to progressive
loss of nigro-striatal DAergic neurons in PD.
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